PMDA drug package insert

ヘパフィルド透析用150単位/mLシリンジ20mL

PMDA Prescription drug · 株式会社大塚製薬工場 · package insert Jul 31, 2024

Key facts

Brand names ヘパフィルド透析用150単位/mLシリンジ20mL, ヘパフィルド透析用200単位/mLシリンジ20mL, ヘパフィルド透析用250単位/mLシリンジ20mL
Nonproprietary names ヘパリンナトリウム
Companies 製造販売元/株式会社大塚製薬工場, 販売元/株式会社ジェイ・エム・エス
Product type Prescription drug
Therapeutic category 血液凝固阻止剤
Therapeutic category codes 873334
YJ codes 3334402G8042, 3334402P1048, 3334402P2028
Approval numbers 22300AMX00623, 22300AMX00624, 21800AMZ10242
Package insert edition 第5版
Package insert date Jul 31, 2024
PMDA document key 180079_3334402G8042_1
PMDA company code 180079

At a glance

  • 1–9 Package insert revisions
  • 10–99 Related PMDA documents
  • None Safety communications
  • No PMDA review report published
  • No Risk management plan (RMP)

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMDA approved drugs and package inserts (Japan)

Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.

Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date:

Browse all PMDA approved drugs and package inserts (Japan)